|
Andrew J. Drug treatment of parkinson’s disease in the 1990s achievrments and future possibilities. Drugs 1997; 53(2): 195-205 Anthony J. Managing medication in the elderly. Hospital Practice 1995; 15: 59-64. Bernard M. and John P. Projecting future drug expenditures — 2000. American Journal of Health-system Pharmacists 2000; 57: 129-138 David C., Robert A. and Matcheri S. Managing Antipsychotic-induced parkinsonism. Drug Safety 1999; 20(3): 269-275 David P., Gregory J., Thomas L., Robert J. and David R. Classification of tremor and update on treatment. American Family Physician 1999; 59(6): 1565-1572. Ellen D. and Dileep B. Development of dissolution tests for oral extended-release products 1998; 3: 128-135 FIP Guidelines for dissolution testing of solid oral products (final draft, 1995). Drug Information Journal, 1996;30: 1071-1084 Gabor S., Helen F., Linda C., Alfred H., Dicky W., Siu-Wah L., Siu-Ning Chiu., Francis C., and Tony L., Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic Schizophrenia. Journal of Clinical Psychopharmacology 1999; 19(2): 141-147 Goskondu V.R., Reddy I.K., Durrani M.J., Wilber W., and Khan M.A. Solid-state stability assessment of controlled release tablets containing Carbopol® 971P. Journal of Controlled Release 1998; 54: 87-93 Grimaldi R., Perucca E. and Ruberto G. Phrmacokinetic and pharmacodynamic studies following intravenous and oral administration of the antiparkinsonian drug biperiden in normal subjects. European Journal of Clinical Pharmacology 1986; 30: 735-737. Guidance for industry: dissolution testing of immediate release solid oral dosage forms. U.S. department of health and human services Food and Drug Administration., Center for Drug Evaluation and Research.,1997. Hollmann M., Brode E., Greger G., Muller-Peltzer H. and Wetzelsberger N. Biperiden effects and plasma levels in volunteers. European Journal of Clinical Pharmacology 1984; 27: 619-621. James E. and Singh G. Method to compare dissolution profiles Drug Information Journal 1996; 30: 1113-1120 James E. Dependence of In vitro/in vivo correlation analysis acceptability on model selection. Pharmaceutical Development and Technology 1999; 4: 89-96 James E., John R., and Gordon L., Nonel approach to the analysis of in vitro/in vivo relationships. Journal of Pharmaceutical Sciences. 1996; 85: 753-759 James E., Singh G., Larry L. and Vinod P. Method to compare dissolution profiles and a rationale for wide dissolution specification for metoprolol tartrate tablets. Journal of Pharmaceutical Sciences 1997; 86(6): 690-700 Jeffrey W. and Henry H. Mathematical comparison of dissolution profiles. Pharmaceutical Technology 1996; 6: 64-74. Lake O.A., Olling M., Barends D.M. In vitro/in vivo correlations of dissolution data of casbamazepine immediate release tablets with pharmapharmacokinetic data obtained in healthy volunteers. European Journal of Pharmaceutics and Biopharmaceutics 1999; 48:13-19 Le Bris Th., and Brode E. Capillary gas chromatographic determination of biperiden in human plasma. Drug Research 1985; 35: 149-151 Lewis J. In vitro/in vivo correlations. Drug Information Journal 1995; 29: 903-915 Lisa C. and Stephen R. Management of acute extrapyramindal effects induced by antipsychotic drugs. American Journal of Health-system Pharmacists 1997; 54(1): 2461-2473 Manuela C., Roberto R., Fiorenzo A., and Agostino B. Pharmaco-kinetic optimization in the treatment of Parkinson’s disease. Clinical Pharmacokinetic 1996; 30(6): 463-481. Oy O.y. Determination of biperiden in human serum by glass capillary gaschromatography with isothermal splitless injection and nitrogen-sensitive detection. Journal of Chromatography 1981; 226: 488-491 Peter N., Hans W. and Rene S. Acute dystonia induced by drug treatment. British Medical Journal 1999; 319: 623-626. The Merck Index. 10thrd., Merck & CO., Inc., 1996; 1238 The United States Pharmacopeia XXIII and the National Formulary XVIII. Unuted States Pharmacopeial Convention, Inc., MD.,1995; 207 Warren C. and William C. An algorithm (decision tree) for the management of parkinson’s disease: treatment guideline. Neurology 1998; 50(Suppl 3): S1-S57 Yokogawa K., Nakashima E., and Ichimura F. Effect of fat tissue volume on the distribution kinetics of biperiden as a function of age in rats. Drug Metabolism and Disposition 1990; 18: 258-263 Yokogawa K., Nakashima E., Ichimura F., and Yamana T. Fundamental pharmacokinetic properties of biperiden: tissue distribution and elimination in rabbits. Journal Pharmacobio-dynamics. 1986; 9:409-416 Yokogawa K., Nakashima E., Ichimura F., and Yamana T. Simultaneous microdetermination of biperiden, haloperidol, and Trihexyphenidyl in plasma and its application to pharmacokinetic analysis after concomitant intravenous administration of the drugs to rabbits. Chemical & Pharmaceutical. Bulletin. 1985; 33: 4581-4586 Yokogawa K., Nakashima E., Ichimura F., Hashimoto T., and Tsuji A. Effect of fasting on biperiden pharmacokinetics in the rat. Journal of Pharmaceutical Sciences 1987; 76: 10-13 中央健康保險局http:// www.nhi.gov.tw
|